In a recent update of an ongoing five year clinical trial conducted by the Chicago Blood Cancer Institute, patients with relapsing-remitting multiple sclerosis have experienced suppression of disease-related inflammation as a result of hematopoietic stem cell transplantations. The stem cells have the ability to regulate the autoimmune attack on the central nervous system, and have provided 82.8% of the patients with two years thus far of event-free disease remission.
In a recent clinical study conducted in Beijing, researchers are testing a treatment for patients suffering from systemic lupus erythematosus by administering autologous [the patient’s own] mesenchymal stem cells. The researchers aim to capitalize on the unique abilities of MSCs to not only differentiate into a multitude of different cell types, but to reduce the autoimmune attack in patients affected by lupus as well.
A recent clinical trial conducted by the University of Genoa has determined that mesenchymal stem cell therapy to treat multiple sclerosis is indeed safe to perform on humans. 27 MS patients completed the study, which comprised an injection of the patient’s own [autologous] mesenchymal stem cells [MSCs] to reduce excessive inflammation caused by the patients’ own immune systems. None of the patients suffered any side effects from the injection.
Topics: limbs, Phase III, traumatic brain injuries, neural stem cells, multiple sclerosis, stemsaveblog, clinical trials, Debilitating Diseases, Phase II, Stemcells, autologousstemcells, Neurodegenerative disease
As reported on the front page of the New York Times Science section, clinical applications of stem cell based therapies are accelerating at a rate that will revolutionize the medical field in a matter of years. In the United States alone, there are currently over 4000 therapies in clinical trials for the treatment of heart disease, blindness, spinal cord injuries, diabetes, H.I.V., and other diseases, injuries, and traumas.
Topics: Muscular Dystrophy, ALS, Parkinson's, Phase III, multiple sclerosis, Heart, stemsaveblog, Joints, Alzheimer's, burn injuries, Diabetes, Acute Myocardial Infarction, Brain, Heart Failure, clinical trials, Bone, Debilitating Diseases, Phase II, Arthritis, Stemcells, Teeth, autologousstemcells, cartilage, Amyotrophic lateral sclerosis, Brain Tumors, Blindness
Researchers from the Wake Forest Baptist Medical Center's Institute for Regenerative Medicine have successfully grown and implanted vaginal organs into four teenage girls born with MRKH Syndrome, a rare condition in which the vagina is undeveloped. The scientists extracted the patient’s own stem cells and placed them onto a biodegradable scaffold of a vagina. The scaffolds were then implanted into the patient’s pelvis, and gradually the stem cells differentiated into a permanent, functional vagina.
A team of researchers from the University of Michigan and the University of Emory reported positive results from a phase 1 clinical study utilizing stem cells to treat amyotrophic lateral sclerosis [ALS], Lou Gehrig’s disease. In addition to verifying the safety of the new procedure, the trial revealed some progress in preventing further disease damage to the motor nerves by improving their cellular environment.
In a recent Phase II clinical study, researchers report that mesenchymal stem cells were successful in relieving chronic lower back pain. The scientists injected MSCs directly into the degenerating vertebral disks of patients suffering from lower back pain, resulting in an overall reduction in the mean pain score, improved function for at least 12 months, and a reduced need for further surgical and non-surgical treatment interventions.
Researchers at the Samsung Medical Center and Biomedical Research Institute in Seoul, South Korea, have succeeded in treating and preventing Bronchopulmonary Dysplasia [BPD], a chronic lung disease affecting preterm infants. In a Phase 1 clinical trial, the research team was successful in transplanting mesenchymal stem cells to repair damage and underdevelopment within the infant’s lungs.
A medical team from the University of Calgary is now recruiting candidates to participate in the phase one clinical trial for a new stem cell therapy that aims to treat spinal cord injuries. The researchers plan to inject stem cells into the spinal cord two sites above and two sites below the point of injury to recreate lost or damaged tissue.
A team of medical researchers at Saint Luc University Clinic have developed a method of repairing bones utilizing autologous [the patient’s own] stem cells. The process involves harvesting the stem cells from the patient, differentiating the stem cells in-vitro to grow bone, pairing the cells with a scaffolding matrix and then molding the material to repair damaged or diseased bone within the patient.